COX-2 in Cancer--A Player That's Defining the Rules
Authors:
Open Access
- 17 April 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 94 (8) , 545-546
Abstract
Cyclooxygenase (COX) inhibitors are being developed as potential agents for the prevention and treatment of cancer after a century of widespread use for inflammation, fever, and pain. Beginning in the late 1970s, researchers noted elevated concentrations of prostaglandins in neoplastic lesions, which suggested a role for arachidonic acid metabolites in tumorigenesis. Multiple lines of evidence—in vitro, in vivo, observational, and clinical—now confirm that COX inhibitors reduce prostaglandin production and the risk of colorectal, skin, and other neoplasias (1). Owing to gastrointestinal safety concerns with traditional nonselective COX inhibitors, derivatives that selectively target COX-2 have been developed for applications in arthritis, analgesia, and the treatment of neoplasia.Keywords
This publication has 13 references indexed in Scilit:
- Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical IssuesJNCI: Journal of the National Cancer Institute, 2002
- National Cancer Institute Workshop on Chemopreventive Properties of Nonsteroidal Anti-Inflammatory Drugs: Role of COX-Dependent and -Independent MechanismsNeoplasia, 2002
- Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2Nature Reviews Cancer, 2001
- Cyclo-oxygenase 2: a pharmacological target for the prevention of cancerThe Lancet Oncology, 2001
- Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic MiceJournal of Biological Chemistry, 2001
- Combinatorial chemoprevention of intestinal neoplasiaNature Medicine, 2000
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Prevention by aspirin and its combination with α-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colonCarcinogenesis, 1999
- Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)Cell, 1996
- Inhibition of Intestinal Carcinogenesis in Rats: Effect of Difluoromethylornithine With Piroxicam or Fish Oil2JNCI: Journal of the National Cancer Institute, 1986